CTT Pharma Reduces Authorized Share Count
CTT Pharmaceuticals Holdings (OTC:CTTH) has announced a significant reduction in its authorized share count, cutting it by 150 million shares from 300 million to 150 million shares. The change has been officially filed with the Delaware Division of Corporations and recorded by the company's stock issuer.
The company states this adjustment reflects its commitment to optimizing its capital structure and creating long-term shareholder value. Additionally, CTT is pursuing approval for an uplisting to the OTCQB market.
CTT Pharmaceuticals Holdings (OTC:CTTH) ha annunciato una significativa riduzione nel numero di azioni autorizzate, diminuendo questo numero di 150 milioni, passando da 300 milioni a 150 milioni di azioni. Il cambiamento è stato ufficialmente registrato presso il Delaware Division of Corporations ed è stato annotato dall'emittente azionario della società.
La società afferma che questo aggiustamento riflette il suo impegno a ottimizzare la sua struttura di capitale e a creare valore per gli azionisti nel lungo termine. Inoltre, CTT sta perseguendo l'approvazione per un uplisting nel mercato OTCQB.
CTT Pharmaceuticals Holdings (OTC:CTTH) ha anunciado una reducción significativa en su número de acciones autorizadas, recortándolo en 150 millones de acciones, pasando de 300 millones a 150 millones de acciones. El cambio se ha registrado oficialmente en la División de Corporaciones de Delaware y ha sido documentado por el emisor de acciones de la empresa.
La compañía declara que este ajuste refleja su compromiso con la optimización de su estructura de capital y la creación de valor a largo plazo para los accionistas. Además, CTT está solicitando la aprobación para un uplisting al mercado OTCQB.
CTT Pharmaceuticals Holdings (OTC:CTTH)는 승인된 주식 수를 300백만 주에서 150백만 주로 1억 5천만 주 줄이는다는 중요한 결정을 발표했습니다. 이 변경 사항은 델라웨어 주 기업부에 공식적으로 제출되었으며, 회사의 주식 발행자가 기록했습니다.
회사는 이 조정이 자본 구조를 최적화하고 장기적으로 주주 가치를 창출하려는 의지를 반영한다고 밝혔습니다. 또한 CTT는 OTCQB 시장으로의 업리스트 인증을 위해 승인 절차를 진행하고 있습니다.
CTT Pharmaceuticals Holdings (OTC:CTTH) a annoncé une réduction significative de son nombre d'actions autorisées, réduisant celui-ci de 150 millions d'actions, passant de 300 millions à 150 millions d'actions. Ce changement a été officiellement enregistré auprès de la Division des Corporations du Delaware et a été documenté par l'émetteur d'actions de l'entreprise.
L'entreprise déclare que cet ajustement reflète son engagement à optimiser sa structure de capital et à créer de la valeur pour les actionnaires à long terme. De plus, CTT cherche à obtenir l'approbation pour une inscription sur le marché OTCQB.
CTT Pharmaceuticals Holdings (OTC:CTTH) hat eine signifikante Reduzierung seiner genehmigten Aktienanzahl angekündigt, indem es diese um 150 Millionen Aktien von 300 Millionen auf 150 Millionen Aktien gesenkt hat. Die Änderung wurde offiziell bei der Delaware Division of Corporations eingereicht und vom Aktienemittenten des Unternehmens registriert.
Das Unternehmen erklärt, dass diese Anpassung sein Engagement zur Optimierung seiner Kapitalstruktur und zur Schaffung von langfristigem Wert für die Aktionäre widerspiegelt. Darüber hinaus verfolgt CTT die Genehmigung für eine Auflistung im OTCQB-Markt.
- Reduction of authorized shares by 50% (from 300M to 150M shares)
- Pursuing uplisting to OTCQB from OTC markets
- None.
TAMPA, FL / ACCESS Newswire / February 3, 2025 / CTT Pharmaceuticals Holdings, Inc. (OTC:CTTH) is pleased to announce a reduction in its authorized share count by 150 million shares. CTT reduced the authorized share count from 300 million shares to 150 million shares. This change has already been filed with Delaware Division of Corporations. Furthermore, CTT's stock issuer has been notified and made the necessary corrections to reflect this change. This latest adjustment demonstrates CTT Pharma's ongoing commitment to optimizing its capital structure and delivering long-term value to shareholders. CTT is also in the process of gaining approval to uplist to the OTCQB and believes this decision benefits existing and future shareholders.
About CTT Pharmaceuticals Holdings, Inc.
CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and deliver drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options and offer better bioavailability.
Investor Relations - 813-606-0060
SOURCE: CTT Pharmaceuticals Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
How many shares did CTT Pharmaceuticals (CTTH) reduce from its authorized share count in February 2025?
What is the new authorized share count for CTT Pharmaceuticals (CTTH)?
Which exchange is CTT Pharmaceuticals (CTTH) planning to uplist to?
How does the share reduction benefit CTTH shareholders?
